Several other equities research analysts have also commented on TECH. BidaskClub raised shares of BIO-TECHNE from a buy rating to a strong-buy rating in a report on Wednesday, April 10th. Zacks Investment Research raised shares of BIO-TECHNE from a sell rating to a hold rating in a report on Saturday, January 5th. Argus reaffirmed a buy rating on shares of BIO-TECHNE in a report on Monday, March 4th. Craig Hallum reaffirmed a hold rating and issued a $179.00 price target (up from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Finally, Stephens raised shares of BIO-TECHNE from an equal weight rating to an overweight rating and set a $180.00 price target on the stock in a report on Monday, January 14th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $188.13.
NASDAQ:TECH opened at $195.27 on Tuesday. BIO-TECHNE has a one year low of $132.75 and a one year high of $206.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.31 and a current ratio of 4.35. The firm has a market capitalization of $7.64 billion, a price-to-earnings ratio of 47.98, a price-to-earnings-growth ratio of 4.56 and a beta of 1.25.
Institutional investors have recently modified their holdings of the business. Executive Wealth Management LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $38,000. First Hawaiian Bank raised its position in shares of BIO-TECHNE by 59.9% in the first quarter. First Hawaiian Bank now owns 219 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 82 shares during the period. Portfolio Solutions LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $50,000. We Are One Seven LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $121,000. Finally, ETF Managers Group LLC raised its position in shares of BIO-TECHNE by 18.1% in the fourth quarter. ETF Managers Group LLC now owns 869 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 133 shares during the period. Institutional investors and hedge funds own 93.94% of the company’s stock.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Featured Story: How does inflation affect different investments?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.